Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced a poster presentation at the upcoming Keystone Symposia’s Obesity: Causes and Consequences meeting, to be held February 4 – 6, 2024, in Vancouver, BC, Canada. Scholar Rock will present preclinical data evaluating SRK-439 in combination with GLP-1 receptor agonists in obesity to maintain lean mass and enhance fat mass loss.

“Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as effective treatments with rapid implementation for obesity, a recognized global epidemic. However, the weight loss resulting from GLP-1 RA treatment has been shown to be associated with significant loss of lean muscle mass. Retaining muscle mass is critical to overall metabolic health, including improved glucose metabolism, insulin sensitivity, bone density and strength. These data support the potential of SRK-439 to support healthier, safer, and more sustainable weight loss with GLP-1 RA therapy,” said Mo Qatanani, Ph.D., Senior Vice President and Head of Research at Scholar Rock.

Details of the presentation are as follows:

Title: SRK-439, a Selective Anti-Pro and Latent Myostatin Antibody, Maintains Lean Mass and Enhances Fat Mass Loss in Models of Pharmacologically Induced Weight Loss
Presentation type: Poster presentation
Presenter: Melissa Fulham, PhD, Senior Scientist II, Scholar Rock
Date and time: Monday, February 5, 2024, 7:30 PM PST
Location: Fairmont Hotel Vancouver, Vancouver, BC, Canada

For conference information, visit https://www.keystonesymposia.org/

Abstracts will be viewable to registered attendees 7 days in advance of the conference. The presentation will be made available in the Publications & Posters section of Scholar Rock’s website following the presentation.

About SRK-439

SRK-439 is a novel, preclinical, investigational myostatin inhibitor that has high in vitro affinity for pro- and latent myostatin and maintains myostatin specificity (i.e., no GDF11 or Activin-A binding), and is initially being developed for the treatment of obesity. Based on preclinical data, SRK-439 has the potential to support healthier weight management by preserving lean mass. The efficacy and safety of SRK-439 have not been established and SRK-439 has not been approved for any use by the FDA or any other regulatory agency.